No cases of endophthalmitis after 20,293 intravitreal injections in an operating room setting

Retina

Volumn 34, Issue 5, 2014, Pages 951-957

  Brynskov, Troels ^a,b   Kemp, Henrik ^a   Sørensen, Torben L ^a,b  

^a Mental Health Services CPH   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Anti VEGF; endophthalmitis; Intravitreal injection; Povidone iodine; Safety; Vascular endothelial growth factor

Indexed keywords

AFLIBERCEPT; ANTIBIOTIC AGENT; CHLORHEXIDINE; FUSIDATE SODIUM; GATIFLOXACIN; GENTAMICIN; LIDOCAINE; OXYBUPROCAINE; POVIDONE IODINE; RANIBIZUMAB; TETRACAINE; TOBRAMYCIN; ANGIOGENESIS INHIBITOR; ANTIINFECTIVE AGENT; TOPICAL ANTIINFECTIVE AGENT; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTICLE; CATARACT EXTRACTION; CONJUNCTIVA; DENMARK; DIABETES MELLITUS; ENDOPHTHALMITIS; FACE MASK; FOLLOW UP; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; OPERATING ROOM; POSITIVE END EXPIRATORY PRESSURE; PREOPERATIVE PERIOD; PROGNOSIS; RETINA MACULA AGE RELATED DEGENERATION; UNIVERSITY HOSPITAL; ANTAGONISTS AND INHIBITORS; CLINICAL PRACTICE; EPIDEMIOLOGY; EYE INFECTIONS, BACTERIAL; GAS MASK; MICROBIOLOGY; RETINAL DISEASES; STATISTICS AND NUMERICAL DATA;

ANGIOGENESIS INHIBITORS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; DENMARK; ENDOPHTHALMITIS; EYE INFECTIONS, BACTERIAL; HUMANS; INTRAVITREAL INJECTIONS; OPERATING ROOMS; PHYSICIAN'S PRACTICE PATTERNS; POVIDONE-IODINE; RESPIRATORY PROTECTIVE DEVICES; RETINAL DISEASES; TOBRAMYCIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84899975756     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000071     Document Type: Article

References (54)

1. Wykoff CC, Flynn HW, Rosenfeld PJ. Prophylaxis for endophthalmitis following intravitreal injection: antisepsis and antibiotics. Am J Ophthalmol 2011;152:717-719.
2. van der Reis MI, La Heij EC, De Jong-Hesse Y, et al. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina 2011;31:1449-1469.
3. McCannel CA. Meta-Analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina 2011;31:654-661.
4. Green-Simms AE, Ekdawi NS, Bakri SJ. Survey of intravitreal injection techniques among retinal specialists in the United States. Am J Ophthalmol 2011;151:329-332.
5. Casparis H, Wolfensberger TJ, Becker M, et al. Incidence of presumed endophthalmitis after intravitreal injection performed in an operating room: a Retrospective Multicenter Study. Retina 2013.
6. Falk MK, Kemp H, Sørensen TL. Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment. Am J Ophthalmol 2013;155:89-95. e3.
7. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998;17: 857-872.
8. Abell RG, Kerr NM, Allen P, et al. Intravitreal injections: is there benefit for a theatre setting? Br J Ophthalmol 2012;96:1474-1478.
9. Rasmussen A, Bloch SB, Fuchs J, et al. A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration. Ophthalmology 2013;120: 2630-2636.
10. Mithal K, Mathai A, Pathengay A, et al. Endophthalmitis following intravitreal anti-VEGF injections in ambulatory surgical centre facility: incidence, management and outcome. Br J Ophthalmol 2013;97:1609-1612.
11. Shimada H, Hattori T, Mori R, et al. Minimizing the endophthalmitis rate following intravitreal injections using 0. 25% povidone-iodine irrigation and surgical mask. Graefes Arch Clin Exp Ophthalmol 2013;251:1885-1890.
12. Moshfeghi AA, Rosenfeld PJ, Flynn HW, et al. Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center. Retina 2011;31:662-668.
13. Fintak DR, Shah GK, Blinder KJ, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 2008;28:1395-1399.
14. Pilli S, Kotsolis A, Spaide RF, et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol 2008;145:879-882.
15. Chen E, Lin MY, Cox J, et al. Endophthalmitis after intravitreal injection: the importance of viridans streptococci. Retina 2011;31:1525-1533.
16. Cheung CSY, Wong AWT, Lui A, et al. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology 2012;119:1609-1614.
17. Diago T, McCannel CA, Bakri SJ, et al. Infectious endophthalmitis after intravitreal injection of antiangiogenic agents. Retina 2009;29:601-605.
18. Shah CP, Garg SJ, Vander JF, et al. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmology 2011;118:2028-2034.
19. Lima LH, Zweifel SA, Engelbert M, et al. Evaluation of safety for bilateral same-day intravitreal injections of antivascular endothelial growth factor therapy. Retina 2009;29: 1213-1217.
20. Artunay O, Yuzbasioglu E, Rasier R, et al. Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection. Eye (Lond) 2009;23:2187-2193.
21. Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013;382:1258-1267.
22. Inman ZD, Anderson NG. Incidence of endophthalmitis after intravitreal injection of antivascular endothelial growth factor medications using topical lidocaine gel anesthesia. Retina 2011;31:669-672.
23. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-1349.
24. Mason JO, White MF, Feist RM, et al. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina 2008;28:564-567.
25. Busbee BG, Ho AC, Brown DM, et al. Twelve-month efficacy and safety of 0. 5 mg or 2. 0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2013;120:1046-1056.
26. Holz FG, Bandello F, Gillies M, et al. Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme. Br J Ophthalmol 2013;97:1161-1167.
27. Schmidt-Erfurth U, Kaiser PK, Korobelnik J-F, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration. Ophthalmology 2013.
28. Singer MA, Awh CC, Sadda SV, et al. HORIZON: an openlabel extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2012;119:1175-1183.
29. Kodjikian L, Souied EH, Mimoun G, et al. Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology 2013;120:2300-2309.
30. Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011;118:1594-1602.
31. Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions. Ophthalmology 2012;119:802-809.
32. Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013;120:2013-2022.
33. Boyer DS, Heier JS, Brown DM, et al. A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009;116: 1731-1739.
34. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
35. Klein KS, Walsh MK, Hassan TS, et al. Endophthalmitis after anti-VEGF injections. Ophthalmology 2009;116:1225-1225. e1.
36. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65. e5.
37. Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011;118:2041-2049.
38. Lad EM, Maltenfort MG, Leng T. Effect of lidocaine gel anesthesia on endophthalmitis rates following intravitreal injection. Ophthalmic Surg Lasers Imaging 2012;43:115-120.
39. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology 2012;119:1388-1398.
40. Bhavsar AR, Googe JM, Stockdale CR, et al. Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials. Arch Ophthalmol 2009;127:1581-1583.
41. Inoue M, Kobayakawa S, Sotozono C, et al. Evaluation of the incidence of endophthalmitis after intravitreal injection of antivascular endothelial growth factor. Ophthalmologica 2011; 226:145-150.
42. Singerman LJ, Masonson H, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol 2008;92: 1606-1611.
43. Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin-): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2007;246:81-87.
44. Wen JC, McCannel CA, Mochon AB, et al. Bacterial dispersal associated with speech in the setting of intravitreous injections. Arch Ophthalmol 2011;129:1551-1554.
45. Miño de Kaspar H, Chang RT, Singh K, et al. Prospective randomized comparison of 2 different methods of 5% povidone-iodine applications for anterior segment intraocular surgery. Arch Ophthalmol 2005;123:161-165.
46. Berkelman RL, Holland BW, Anderson RL. Increased bactericidal activity of dilute preparations of povidone-iodine solutions. J Clin Microbiol 1982;15:635-639.
47. Yin VT, Weisbrod DJ, Eng KT, et al. Antibiotic resistance of ocular surface flora with repeated use of a topical antibiotic after intravitreal injection. JAMA Ophthalmol 2013;131: 456-461.
48. Milder E, Vander J, Shah C, et al. Changes in antibiotic resistance patterns of conjunctival flora due to repeated use of topical antibiotics after intravitreal injection. Ophthalmology 2012;119:1420-1424.
49. Costello P, Bakri SJ, Beer PM, et al. Vitreous penetration of topical moxifloxacin and gatifloxacin in humans. Retina 2006; 26:191-195.
50. Halachimi-Eyal O, Lang Y, Keness Y, et al. Preoperative topical moxifloxacin 0. 5% and povidone-iodine 5. 0% versus povidone-iodine 5. 0% alone to reduce bacterial colonization in the conjunctival sac. J Cataract Refract Surg 2009;35:2109-2114.
51. Moss JM, Sanislo SR, Ta CN. A prospective randomized evaluation of topical gatifloxacin on conjunctival flora in patients undergoing intravitreal injections. Ophthalmology 2009;116: 1498-1501.
52. Lyall DAM, Tey A, Foot B, et al. Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes. Eye (Lond) 2012;26:1517-1526.
53. Moss JM, Sanislo SR, Ta CN. Antibiotic susceptibility patterns of ocular bacterial flora in patients undergoing intravitreal injections. Ophthalmology 2010;117:2141-2145.
54. Bhatt SS, Stepien KE, Joshi K. Prophylactic antibiotic use after intravitreal injection: effect on endophthalmitis rate. Retina 2011;31:2032-2036.